Table 4.
Univariate Cox regression analyses for MACE
| Variables | HR | HR95%CI | p-value |
|---|---|---|---|
| Male | 0.86 | 0.66–1.13 | 0.288 |
| Age | 1.03 | 1.02–1.05 | < 0.001 |
| Previous MI | 1.17 | 0.87–1.58 | 0.308 |
| Previous stroke | 1.32 | 0.96–1.84 | 0.092 |
| Previous PCI | 0.87 | 0.56–1.33 | 0.516 |
| Admission for MI | 0.82 | 0.59–1.16 | 0.262 |
| Hypertension | 1.27 | 0.97–1.66 | 0.086 |
| DM | 1.30 | 1.01–1.69 | 0.049 |
| Hyperlipidemia | 1.16 | 0.90–1.51 | 0.256 |
| FH-CAD | 0.95 | 0.70–1.31 | 0.770 |
| LVEF | 0.16 | 0.05–0.47 | 0.001 |
| TC | 1.22 | 1.12–1.33 | < 0.001 |
| eGFR | 0.99 | 0.99–1.00 | 0.006 |
| LDL-C | 1.14 | 1.00–1.31 | 0.057 |
| Antiplatelet drugs | 0.88 | 0.28–2.74 | 0.820 |
| Beta-blockers | 0.46 | 0.33–0.63 | < 0.001 |
| Statins | 1.20 | 0.85–1.68 | 0.303 |
| ACEI/ARB | 1.06 | 0.76–1.48 | 0.736 |
| Hypoglycemic drugs | 1.15 | 0.86–1.53 | 0.348 |
| METS-IR | 1.05 | 1.03–1.06 | < 0.001 |
| MEST-IR (Per SD) | 1.36 | 1.20–1.54 | < 0.001 |
MACE the major adverse cardiovascular events, HR hazard ratio, CI confidence interval, MI myocardial infarction, PCI percutaneous transluminal coronary intervention, DM diabetes mellitus, FH-CAD family history of coronary artery disease, LVEF left ventricle ejection fraction, TC total cholesterol, eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein-cholesterol, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, METS-IR the metabolic score for insulin resistance
p values in bold are < 0.05